Rinossinusites em crian？as infectadas pelo HIV sob terapia anti-retroviral

the association of protease inhibitors (pi) to antiretroviral therapy has generated sensible changes in morbidity and mortality of hiv-infected patients. aim: aims at evaluating the impact of this association on the prevalence of rhinosinusitis (rs) and cd4+ lymphocyte count in hiv-infected children. methods: retrospective cross-sectional study of the medical charts of 471 hiv-infected children. in 1996, protease inhibitors were approved for use as an association drug in antiretroviral therapy. children were divided into two groups: one which did not receive pi and another which received pi after 1996. the prevalence of rs and cd4+ lymphocyte counts were compared between these groups. results: 14.4% of hiv-infected children had rs. chronic rs was more prevalent the its acute counterpart. children under 6 years old who were taking protease inhibitors presented with a significant higher prevalence of acute rs. the association of pi with the antiretroviral regimen was associated to higher mean cd4+ lymphocyte count and lower prevalence of chronic rs. conclusions: the use of protease inhibitors was associated to higher mean cd4+ lymphocyte count. children under 6 years of age in antiretroviral therapy associated with pi presented a lower likelihood of developing chronic rs.